Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

[Optic neuritis: diagnosis, treatment and clinical implications].
CCSVI is associated with multiple sclerosis.
A Genome-Wide Integrative Genomic Study Localizes Genetic Factors Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1).
Mesenchymal Stem Cell treatment for autoimmune diseases: a critical review.
Heat Shock Protein 70: Roles in Multiple Sclerosis.
Large-scale neuronal network dysfunction in multiple sclerosis?: Evidence from resting-state fMRI.
Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.
Compressive syndrome of internal jugular veins in multiple sclerosis: does it matter?
Training in MS: influence of two different endurance training protocols (aquatic versus overland) on cytokine and neurotrophin concentrations during three week randomized controlled trial.
Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS.
Lack of response to rituximab therapy in patients with neuromyelitis optica: Response to Kim and Kim.
Practical medical applications of quantitative MR relaxometry.
Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation.
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.
Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor
[Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
Effects of multidisciplinary rehabilitation on chronic fatigue in multiple sclerosis: a randomized controlled trial.
MR Imaging in Multiple Sclerosis: The Accuracy of 3D Double Inversion Recovery at 3 Tesla and the Potential for Single Sequence Imaging.
Cerebral venous sinus thrombosis in the patient with multiple sclerosis associated with congenital antithrombin deficiency.
Epigenetic changes in neurology: DNA methylation in multiple sclerosis.
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Soluble adenylyl cyclase is necessary and sufficient to overcome the block of axonal growth by myelin-associated factors.
Review: the role of vitamin D in nervous system health and disease.
Neurotrophic factors and their effects in the treatment of multiple sclerosis.

Pages